Unternehmen

Mineralys Therapeutics

Mineralys Therapeutics is a publicly traded, clinical-stage biotechnology company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. Our initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that we are developing for cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease.

Mineralys is a fully remote company.

For more information, please visit https://mineralystx.com. Follow Mineralys on LinkedIn.